Prostate Cancer Clinical Trial
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
Summary
The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to subjects followed on active surveillance as standard of care.
Full Description
The ProVent Study is designed to look at subjects who recieve sipuleucel-T compared to control subjects followed on AS. The study will enroll subjects being followed by AS and initially diagnosed within 12 months prior to Screening with either ISUP Grade Group 1 or 2 adenocarcinoma of the prostate.
The Screening Phase will begin at the completion of the informed consent process and continues until randomization. After Screening assessments are completed, eligible subjects will be randomized 2:1 to the sipuleucel-T arm or the control arm. Subjects randomized to sipuleucel-T arm will receive product as described in the sipuleucel-T approved label.
Subjects will undergotheir first leukapheresis within 60 days of randomization.
Subjects randomized to the control arm will be followed on AS. The Active Phase will begin at randomization and continues through completion of the end of Active Phase study visit (within 30 days of Biopsy 2). Once a subject from either the sipuleucel-T or control arms completes the end of Active Phase visit, they will enter the Follow-up Phase and complete Follow-up Phase visits every 6 months starting from their last Active Phase visit. The Follow-up Phase visits end when the last subject enrolled completes Biopsy 2 and end of Active Phase visit or until the study is terminated by the sponsor.
Eligibility Criteria
Inclusion Criteria:
1. Age is ≥ 18 years
2. Written informed consent provided prior to the initiation of study procedures
3. Histologically proven adenocarcinoma of the prostate initially diagnosed ≤12 months of Screening. All biopsy slides with subject information redacted must be submitted for BICR.
4. Prostate cancer diagnosis determined by BICR as one of the following: 4a. ISUP Grade Group 1 with 3 or more cores positive from a systematic (≥10 cores) biopsy 4b. ISUP Grade Group 1 with ≥ 1 core positive with ≥50% cancer involvement from a systematic (≥10 cores) biopsy 4c. ISUP Grade Group 1 from 3 or more positive cores from any combination of cores from a systematic (≥10 cores) biopsy and MRI targeted biopsy (note: multiple cores from each MRI targeted lesion will count as 1 core) 4d. ISUP Grade Group 1 from a negative systematic (≥10 cores) biopsy and an MRI targeted core positive with ≥50% cancer involvement 4e. ISUP Grade Group 2 from a systematic (≥10 cores) biopsy with <50% of the total number of any cores positive for cancer 4f. ISUP Grade Group 2 from a negative systematic (≥10 cores) biopsy and MRI targeted core(s) positive for Gleason 3+4 (see note below) 4g. ISUP Grade Group 2 from any combination of cores from a systematic (≥10 cores) biopsy and MRI targeted biopsy (see note below)
Note for 4f and 4g: the total number of positive cores must be <50% of total cores from both the systematic biopsy and MRI targeted lesions; each MRI targeted lesion, irrespective of multiple positive cores, will each count as 1 core for the total number of positive cores, e.g., 4 targeted lesions with 2 positive cores each will only add 4 to the total core count.
5. Subject consents to standard of care for biopsy frequency of 2 on-study prostate biopsies and to provide biopsy tissue for study endpoint analysis.
6. Estimated life expectancy ≥ 10 years
7. Candidate for primary curative therapy (e.g., surgery or radiation) if prostate cancer progression occurs
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
9. Adequate baseline hematologic, renal, and liver function tests as evidenced by laboratory test results within the following ranges ≤30 days prior to randomization White blood cell (WBC) count ≥ 3.0 x 10^6 cells/mL Absolute neutrophil count (ANC) ≥ 1.5 x 10^6 cells/mL Platelet count ≥ 1.0 x10^5 cells/uL Hemoglobin (Hgb) ≥ 10.0 g/dL Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Alanine aminotransferase (ALT) ≤ 2.0 x ULN Aspartate aminotransferase (AST) ≤ 2.0 x ULN
Exclusion Criteria:
1. Former therapy for prostate cancer (local or systemic)
2. Any previous prostatic surgical procedure that significantly changes the anatomy of prostate (at the discretion of sponsor's Medical Monitor)
3. Any investigational product received for prostate cancer
4. Prostate biopsy specimen reveals neuroendocrine or small cell features
5. Primary Gleason score is ≥ 4 or any Gleason pattern 5
6. Any evidence of locally advanced, regional or metastatic disease, including regional and distant lymph node enlargement (Nodes ≥1.5 cm in the short axis are considered pathologic and measurable)
7. A history of a cerebrovascular event (CVE) or transient ischemic attack (TIA)
8. Subject has used a 5-alpha-reductase inhibitor (e.g., finasteride or dutasteride) continuously for ≥ 6 months and within 6 months prior to study Screening
9. Subject has a history of any other stage I-IV malignancy, except for basal or squamous cell skin cancer. The subject must be disease free and off any malignancy-related treatment for at least 5 years.
10. Subject has prior use within 30 days of study Screening of any herbal, dietary, or alternative anti-cancer treatment or product, such as PC-SPES (or PC-x product), saw palmetto, ketoconazole, an estrogen-containing nutraceutical, or high dose calcitriol (>0.5 μg/day). The Investigator will consider herbal therapies on a case-by-case basis to determine whether they fall into the category of prohibited medications based on their potential for hormonal or anti-cancer or anti-cancer properties.
11. Need for systemic chronic immunosuppressive therapy (e.g., anti-tumor necrosis factor alpha monoclonal antibodies, glucocorticoids)
12. Uncontrolled, concurrent illness including, but not limited to the following: ongoing or active infection (bacterial, viral, or fungal), symptomatic congestive heart failure (New York Classification III-IV) or unstable angina pectoris within the last 6 months, or psychiatric illness that would limit compliance with study requirements as well as any condition that would preclude a subject from undergoing leukapheresis (e.g., within the previous 6 months: myocardial infarction, interventional cardiology procedure such as angioplasty or stent placement, pulmonary embolism or deep vein thrombosis).
13. Hypogonadal (T <175 ng/dL) or on continuous testosterone replacement therapy
14. Positive serology for HIV-1, HIV-2 or HTLV-1, HTLV-2
15. Active hepatitis B or C
16. Any medical intervention, any other condition, or any other circumstance which, in the opinion of the investigator or the sponsor's Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study's objectives.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 53 Locations for this study
Gilbert Arizona, 85234, United States
Tucson Arizona, 85741, United States
Tucson Arizona, 85741, United States
Little Rock Arkansas, 72211, United States
La Jolla California, 92093, United States
Los Angeles California, 90073, United States
Orange California, 92868, United States
Santa Monica California, 90404, United States
Torrance California, 90505, United States
Aurora Colorado, 80045, United States
Denver Colorado, 80211, United States
Golden Colorado, 80401, United States
Daytona Beach Florida, 32114, United States
Roswell Georgia, 30076, United States
Chicago Illinois, 60612, United States
Chicago Illinois, 60612, United States
Chicago Illinois, 60643, United States
Glenview Illinois, 60026, United States
Glenview Illinois, 60026, United States
Joliet Illinois, 60431, United States
Lake Barrington Illinois, 60010, United States
Jeffersonville Indiana, 47130, United States
West Des Moines Iowa, 50266, United States
Overland Park Kansas, 66211, United States
Wichita Kansas, 67226, United States
New Orleans Louisiana, 70112, United States
Shreveport Louisiana, 71106, United States
Baltimore Maryland, 21224, United States
Bethesda Maryland, 20889, United States
Towson Maryland, 21204, United States
Ann Arbor Michigan, 48109, United States
Troy Michigan, 48084, United States
Southaven Mississippi, 38671, United States
Saint Louis Missouri, 63110, United States
Omaha Nebraska, 68114, United States
Omaha Nebraska, 68130, United States
Mount Laurel New Jersey, 08054, United States
Melville New York, 11747, United States
New York New York, 10029, United States
Syracuse New York, 13210, United States
Raleigh North Carolina, 27612, United States
Cincinnati Ohio, 45212, United States
Oklahoma City Oklahoma, 73104, United States
Springfield Oregon, 97477, United States
Bala-Cynwyd Pennsylvania, 19004, United States
Lancaster Pennsylvania, 17604, United States
Warwick Rhode Island, 02886, United States
Myrtle Beach South Carolina, 29572, United States
Germantown Tennessee, 38138, United States
Nashville Tennessee, 37209, United States
Nashville Tennessee, 37232, United States
Dallas Texas, 75230, United States
San Antonio Texas, 78229, United States
Richmond Virginia, 23235, United States
Virginia Beach Virginia, 23462, United States
Seattle Washington, 98101, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.